Symptoms and General Pathology

All Conditions

Neoplasms

Digestive System Diseases

Constipation

Colonic Neoplasms

Diarrhea

Pain

Melena

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Signs and Symptoms, Digestive

Yan Li, doctor

The incidence risk of colorectal cancer （CRC） is increasing at 4.2% year by year in China. Most effective way to reduce the death rate of CRC patients is to diagnose in quite an early stage. QiaoKou District is a chemical industry Zone of Wuhan with a long history, which has few data of CRC epidemiology. The investigators design the primary CRC screening for this district by healthy questionnaire, Fecal Occult Blood Test(FOBT) and colonoscopy. HanYang Areo has been chosen as Control for its non-industry environment.The crowd would be screen biennially. The high risk group would be intervened, such as resection of polyps or other specific treatment. A follow-up registration database has been built for analysis the relationship between incidence or death rate to high risk factors, such as age, life environment, lifestyles, base diseases and family history of cancer.

This study will provide some epidemiology dates of CRC to the local Government, and assist the governor to built a more effective screening system of CRC.

For this study, you will be asked to complete a personal interview. During the interview, you will be asked questions about your demographics (age, sex, etc.), underlying diseases, lifestyle, family history of cancer, awareness of CRC. It should take around 30 minutes to complete the interview.

Residents in high risk group need to have some special tests, including FOBT and colonoscopy. Intestinal neoplasm will be suggested to biopsy or remove under colonoscopy for pathological examination. All tests are free. The interviews will be performed in Residential area and special tests will be done in the hospital during a regularly scheduled visit to Pu-Ai hospita.You may be contacted at home by phone so that researchers can collect information about any changes in your health status.

Blood sample or neoplasm from high risk group

Epidemiological Study of Colorectal Cancer in WuHan

Wuhan University

Hubei Cancer Hospital

Huazhong University of Science and Technology

Wuhan Iron and Steel Workers' Hospital

Wuhan Pu-Ai Hospital

Diseases and Abnormalities at or Before Birth

Heart and Blood Diseases

Blood and Lymph Conditions

Rare Diseases

Hemorrhage

Congenital Abnormalities

Gastrointestinal Hemorrhage

Telangiectasis

Arteriovenous Malformations

Telangiectasia, Hereditary Hemorrhagic

Angiodysplasia

Hemangioma

Vascular Diseases

Vascular Malformations

Cardiovascular Abnormalities

Neoplasms, Vascular Tissue

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Hemorrhagic Disorders

Hematologic Diseases

Hereditary Hemorrhagic Telangiectasia

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Thalidomide

Immunosuppressive Agents

Immunologic Factors

Anti-Bacterial Agents

Angiogenesis Inhibitors

Growth Inhibitors

Atul Kumar, MD

James Gossage, MD

The purpose of this study is to determine whether Thalidomide is effective in the treatment of arteriovenous malformations in the gastrointestinal tract.

Arteriovenous malformations (AVM's) are the commonest vascular abnormalities of the gut. AVM's or Angiodysplasia may be acquired or inherited as in a hereditary hemorrhagic telangiectasia (HHT). Repeated episodes of gastrointestinal bleeding (GIB), especially in the elderly have been attributed to angiodysplasia. Clinically significant GIB may be also seen in up to 40% of HHT patients, usually in the fourth and fifth decades of life. GIB may manifest both as acute major hemorrhage, slow intermittent blood loss or a combination of these findings and patients may be symptomless, present with acute bleeding or iron deficiency anemia. Recurrent hemorrhage and persistent iron-deficiency anemia is common despite supplemental iron therapy and patients require repeated transfusions. Amongst patients with preexisting co-morbidities, repeated bleeding may lead to significant morbidity and mortality. Furthermore, re-bleeding among these patients consumes a disproportionate share of healthcare resources devoted to multiple admissions, repeated endoscopies and blood transfusions. There are no effective treatment options available currently. The purpose of this study is to determine whether Thalidomide is effective in the treatment of arteriovenous malformations in the gastrointestinal tract.

Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding

Augusta University

University of Massachusetts, Worcester

Northport Veterans Affairs Medical Center

Atul Kumar

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Epidemiological Study of Colorectal Cancer in WuHan	NCT01863303	Diarrhea Constipation Melena Neoplasm Colonic Neoplas... Pain		40 Years - 74 Years	Wuhan Pu-Ai Hospital
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding	NCT00389935	Arteriovenous M... Hereditary Hemo... Hematochezia Melena	Thalidomide	18 Years -	Northport Veterans Affairs Medical Center
Epidemiological Study of Colorectal Cancer in WuHan	NCT01863303	Diarrhea Constipation Melena Neoplasm Colonic Neoplas... Pain		40 Years - 74 Years	Wuhan Pu-Ai Hospital
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding	NCT00389935	Arteriovenous M... Hereditary Hemo... Hematochezia Melena	Thalidomide	18 Years -	Northport Veterans Affairs Medical Center

Spots Global Cancer Trial Database for melena

Every month we try and update this database with for melena cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for melena

Every month we try and update this database with for melena cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for melena cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.